Medifocus
Medifocus, Inc. develops and commercializes minimally invasive focused-heat treatment systems for BPH (Prolieve, FDA-approved) and breast cancer (APA 1000, in Phase III), generating revenue through direct sales to 250+ US urology offices and international distribution partners.
- Company typePublic
- Founded2012
- HeadquartersColumbia, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Medifocus does
Medifocus, Inc. (TSXV-MFS, OTC-MDFZF) is a Columbia, Maryland-based medical device and biotechnology company that develops and commercializes minimally invasive focused-heat treatment systems for cancerous tumors and benign prostatic hyperplasia (BPH). The company owns two proprietary technology platforms: the Endo-thermotherapy Platform, which combines microwave heating with balloon dilatation and is commercialized as the Prolieve® Thermodilatation System for BPH, and the Adaptive Phased Array (APA) Microwave Focusing Platform, licensed from MIT, which underlies the APA 1000 system currently in Phase III clinical trials for breast cancer. Approximately 100 issued and pending US and international patents protect the technology portfolio, supplemented by newly granted Canadian and European patents and a patent-pending Cluster Tissue Ablation extension.
The company generated its first revenue in Q3 FY2012 after acquiring the Prolieve business from Boston Scientific in July 2012 for $5 million, a transaction that included the Rocky Mountain Mobile Services operation. Prolieve is an FDA-approved 45-minute in-office treatment that creates a biological stent effect through combined heat and compression, with 100,000+ cases performed in the US and 5-year follow-up data confirming durability. Medifocus sells Prolieve directly to urology practices (250+ offices), through Rocky Mountain Mobile Services (150+ mobile locations), and via exclusive distribution partners in Israel (Amos Gazit) and across Asia (Hong Kong, with planned expansion to South Korea, Malaysia, Thailand, Singapore, and China). Revenue is generated primarily through Prolieve hardware and recurring disposable catheter kit sales, with CPT code 53850 used for reimbursement. The company has raised approximately $9.3M through private placements and convertible debentures between 2012 and 2014, achieved its first positive operating cash flow in FY2018 ($21,544), and reported $1.44M in revenue for the six months ended September 30, 2018, a 26% increase year-over-year.
Medifocus firmographics
Firmographics- Name
- Medifocus
- Legal name
- Medifocus, Inc.
- Website
- https://medifocusinc.com
- Company type
- Public
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Medifocus, Inc. develops and commercializes minimally invasive focused-heat treatment systems for BPH (Prolieve, FDA-approved) and breast cancer (APA 1000, in Phase III), generating revenue through direct sales to 250+ US urology offices and international distribution partners.
- Ownership category
- akta.pro rank
Where Medifocus is headquartered
LocationHeadquarters
- HQ city
- Columbia
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Medifocus business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Others
Revenue model
- Prolieve Hardware and Disposable Catheter Kits: Revenue generated through sale of Prolieve hardware systems and recurring disposable catheter kit sales to urology practices. Mobile service revenue from Rocky Mountain Mobile Services.
- Prolieve Treatment Revenue: Q3 2018: $704,195; Q3 2017: $557,600. Six months ending Sept 30, 2018: $1,441,585 from $1,266,500 same period 2017.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Prolieve System - In-office BPH treatment |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels6 records
Medifocus product offering
Product offeringCore offering
Medifocus develops and commercializes minimally invasive focused heat treatment systems for cancerous and benign tumors and for enlarged prostate (BPH). Its commercial product, the Prolieve Thermodilatation System, is an FDA-approved 45-minute in-office device combining microwave thermotherapy with balloon dilatation for BPH treatment, and it is advancing the APA 1000 Breast Cancer Treatment System (licensed from MIT) through Phase III clinical trials. Revenue is generated through Prolieve hardware and disposable catheter kit sales, mobile services, and international distribution partners.
Product overview
Medifocus is a biotechnology company with a portfolio of two proprietary focused heat technology platforms and two commercialized products. The Endo-thermotherapy Platform powers the Prolieve® Thermodilatation™ System, an FDA-approved 45-minute in-office treatment for BPH that combines microwave heating with balloon dilatation. The Adaptive Phased Array Microwave Focusing Platform underlies the APA 1000 Breast Cancer Treatment System (licensed from MIT) currently in Phase III clinical trials, which has demonstrated 50% additional tumor shrinkage when combined with chemotherapy. The company generates revenue through Prolieve® catheter kit sales and mobile services, while advancing the APA 1000 through regulatory approval. Approximately 100 issued and pending US and international patents protect the technology portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- Prolieve: FDA-approved Thermodilatation System for treatment of Benign Prostatic Hyperplasia (BPH) - a 45-minute in-office procedure combining microwave thermotherapy with balloon dilatation.
- APA 1000
Products and services
- Prolieve Thermodilatation System FDA-approved medical device that combines microwave thermotherapy with balloon dilatation to treat Benign Prostatic Hyperplasia (BPH). Delivered as a 45-minute in-office procedure under local anesthesia that creates a biological stent effect, providing immediate and long-term relief of BPH symptoms without sedation or post-operative catheterization for ~90% of patients. Sold to urology practices with recurring disposable catheter kit revenue.
- Adaptive Phased Array (APA) 1000 Breast Cancer Treatment System Microwave focusing technology system for breast cancer treatment that precisely targets and controls microwave energy to shrink tumors without side effects on surrounding tissues. Licensed from Massachusetts Institute of Technology and further refined by Medifocus. Currently in Phase III clinical trials.
- Rocky Mountain Mobile Services Wholly-owned mobile service operation that delivers turnkey Prolieve Thermodilatation treatments across more than 150 mobile locations nationwide in the United States. Enables physician offices without in-office equipment to offer Prolieve BPH treatment to their patients on a mobile basis.
Quantifiable outcome
- 50% additional tumor shrinkage when APA system used with chemotherapy vs chemotherapy alone
- +3 more outcomes
Companies that use Medifocus
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Medifocus technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Medifocus partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- Asian Market PartnerscoreAsian partners performing Prolieve procedures reimbursed by insurance carriers in Hong Kong. Expansion into South Korea, Malaysia, Thailand, Singapore, and China markets underway.
- Amos Gazit LtdcoreExclusive distribution agreement to market and distribute Prolieve Thermodilatation System for BPH treatment in Israel. Founded 1958, based in Petach-Tikva, Israel. Leading Israeli company in importing and marketing safety and medical equipment.
- Yuanxing PharmaminorResearch & Development and Manufacturing Agreement for patented heat-activated and tumor-targeted immunotherapy and gene therapy technology.
- Tanaka Kapec Design Group, Inc.minorEngaged as lead designer for next generation Prolieve Thermodilatation System design and development.
- Major Academic Medical CenterminorExclusive agreement to license technology for developing heat-activated and tumor-targeted immunotherapy and gene therapy.
- Euro Japan Marketing LtdcoreEngaged for expansion into Asia Pacific market for both Prolieve and APA 1000 technology.
- Ideal Concept Group, LtdminorJoint venture partnership for strategic market development.
- Boston Scientific CorporationcoreAcquired all assets of Prolieve business including inventory, Rocky Mountain Mobile Services, and intellectual property for $5 million ($2.5M upfront, $2.5M contingent on sales performance). Prolieve technology was originally created by current Medifocus management team.
- Massachusetts Institute of TechnologycoreCore APA microwave focusing technology licensed from MIT. Medifocus has further refined the precision of microwave focusing and control ability for breast cancer treatment.
- Rocky Mountain Mobile ServicescoreMobile distribution assets acquired from Boston Scientific as part of Prolieve business purchase. Provides turnkey, mobile Prolieve services at over 150 mobile locations nationwide.
Scale indicators6 records
Recent moves8 records
Expansion highlights5 records
Medifocus competitors and assessment
Company assessmentBroad incumbents
- Hologic: Women's health medtech leader with a significant breast cancer diagnostics and treatment portfolio; comparable as a peer addressing the same breast cancer patient segment targeted by APA 1000.
- Merit Medical Systems: Diversified medical device manufacturer with a urology and oncology portfolio; comparable as a broader incumbent serving the same urology office customer base that purchases Prolieve.
- Celsion Corporation: Founded by Medifocus founder Dr. Augustine Cheung, Celsion develops heat-based andThermoDox cancer therapies, making it a thematically comparable oncology hyperthermia platform peer.
- Boston Scientific: Original developer and commercializer of the Prolieve system before divesting it to Medifocus in 2012; broader medtech incumbent with a urology portfolio and the resources to potentially re-enter the BPH device space.
- AngioDynamics: Medical device company with oncology and surgical ablation products that overlap with Medifocus's tumor-targeted energy delivery and tissue ablation technologies.
Direct peers
- PROCEPT BioRobotics: Competitor in minimally invasive BPH treatment with its Aquablation therapy; targets the same urology practices and patient population as Prolieve with a differentiated waterjet ablation approach.
- Urologix: Direct competitor that also developed and marketed transurethral microwave thermotherapy (TUMT) systems for BPH treatment, competing head-to-head with Medifocus's Prolieve in the same urology office channel.
Emerging players
- EDAP TMS: Markets High-Intensity Focused Ultrasound (HIFU) systems for prostate and other cancers; comparable as a minimally invasive, energy-based focal therapy company targeting similar oncology indications.
- NxThera (now part of Boston Scientific): Developed the Rezum water vapor thermal therapy system for BPH before being acquired by Boston Scientific; directly comparable minimally invasive heat-based BPH treatment modality.
- Sonablate (Focus Surgery): Developer of HIFU technology for prostate disease and BPH; competes in the same minimally invasive, energy-based urology treatment category as Prolieve.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Medifocus social profiles
Digital presenceMedifocus compliance and trust
Trust signalCompliance3 records
Medifocus financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medifocus leadership team
Management profileNumber of profiles
Profiles14 records
Medifocus subsidiaries and ownership
Company hierarchySubsidiaries1 record
Medifocus funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medifocus M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medifocus
What does Medifocus do?
Medifocus develops and commercializes minimally invasive focused heat treatment systems for cancerous and benign tumors and for enlarged prostate (BPH). Its commercial product, the Prolieve Thermodilatation System, is an FDA-approved 45-minute in-office device combining microwave thermotherapy with balloon dilatation for BPH treatment, and it is advancing the APA 1000 Breast Cancer Treatment System (licensed from MIT) through Phase III clinical trials. Revenue is generated through Prolieve hardware and disposable catheter kit sales, mobile services, and international distribution partners.
Is Medifocus a public or private company?
Medifocus is a public company. It is classified as public and is currently operating.
When was Medifocus founded?
Medifocus was founded in 2012. It employs 1 to 10 people.
Where is Medifocus based?
Medifocus is headquartered in Columbia, United States, in the North America region.
How does Medifocus make money?
Two revenue lines are on record. Prolieve Hardware and Disposable Catheter Kits are the primary driver. The others are prolieve Treatment Revenue.
Who are Medifocus's main competitors?
Broad incumbents on record are Hologic, Merit Medical Systems, Celsion Corporation, Boston Scientific and AngioDynamics. Direct peers are PROCEPT BioRobotics and Urologix. Emerging players are EDAP TMS, NxThera (now part of Boston Scientific) and Sonablate (Focus Surgery).
Does Medifocus have an API?
No public API is recorded for Medifocus.